UBS Group’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

UBS Group’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-58,035	Closed	-$1.62M	–	8742
2019 Q3	$1.62M	Buy	58,035 +57,191	+6,776%	+$927K	﹤0.01%	3513
2019 Q2	$12K	Buy	844 +544	+181%	+$5.17K	﹤0.01%	6987
2019 Q1	$3K	Sell	300 -1,534	-84%	-$12.5K	﹤0.01%	7397
2018 Q4	$14K	Sell	1,834 -445	-20%	-$7.17K	﹤0.01%	7070
2018 Q3	$48K	Buy	2,279 +1,279	+128%	+$30.5K	﹤0.01%	6195
2018 Q2	$30K	Buy	+1,000	New	+$27.2K	﹤0.01%	6398
2017 Q4	–	Sell	-94	Closed	-$2K	–	8267
2017 Q3	$2K	Sell	94 -2,406	-96%	-$57K	﹤0.01%	7523
2017 Q2	$56K	Buy	+2,500	New	+$52.6K	﹤0.01%	5574

UBS Group's DOVA Position: Q4 2019 in Review

UBS Group sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 58,035 shares — an estimated $1.62M sold.

UBS Group first reported a position in DOVA in Q2 2017 and held it in 8 quarters. The position peaked at $1.62M in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

UBS Group reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
UBS Group sold 58,035 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $1.62M.
UBS Group first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
UBS Group's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.62M in Q3 2019.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.